Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) Other Operating Expenses (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Other Operating Expenses for 17 consecutive years, with $94.9 million as the latest value for Q1 2026.

  • Quarterly Other Operating Expenses rose 1.49% to $94.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $349.6 million through Jan 2026, down 3.88% year-over-year, with the annual reading at $343.1 million for FY2026, 5.65% down from the prior year.
  • Other Operating Expenses for Q1 2026 was $94.9 million at Usana Health Sciences, up from $77.7 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $161.2 million in Q1 2022, with the low at $77.7 million in Q3 2025.
  • Average Other Operating Expenses over 5 years is $100.2 million, with a median of $95.8 million recorded in 2024.
  • The sharpest move saw Other Operating Expenses tumbled 39.28% in 2022, then grew 1.49% in 2026.
  • Over 5 years, Other Operating Expenses stood at $97.9 million in 2022, then dropped by 2.04% to $95.9 million in 2023, then fell by 2.48% to $93.5 million in 2024, then dropped by 16.92% to $77.7 million in 2025, then grew by 22.15% to $94.9 million in 2026.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $94.9 million, $77.7 million, and $87.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.